MCKESSON CORP (MCK) Stock Price, Forecast & Analysis
USA - NYSE:MCK - US58155Q1031 - Common Stock
MCK Key Statistics, Chart & Performance
The current stock price of MCK is 836.43 USD. In the past month the price increased by 10.66%. In the past year, price increased by 33.82%.
MCK Latest News, Press Relases and Analysis
MCK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COR | CENCORA INC | 22.3 | 66.97B | ||
| CAH | CARDINAL HEALTH INC | 21.9 | 46.36B | ||
| HSIC | HENRY SCHEIN INC | 15.15 | 8.56B | ||
| AHCO | ADAPTHEALTH CORP | 33.02 | 1.38B | ||
| AHG | AKSO HEALTH GROUP | N/A | 889.71M | ||
| OMI | OWENS & MINOR INC | 2.67 | 266.09M | ||
| WGRX | WELLGISTICS HEALTH INC | N/A | 59.97M | ||
| ATPC | AGAPE ATP CORP | N/A | 65.99M | ||
| COSM | COSMOS HEALTH INC | N/A | 21.13M | ||
| VRAX | VIRAX BIOLABS GROUP LTD | N/A | 2.29M | ||
| POM | POMDOCTOR LTD - ADR | N/A | 696.42M |
Related stock screener links
About MCK
Company Profile
McKesson Corp. engages in providing healthcare services. The company is headquartered in Irving, Texas and currently employs 43,000 full-time employees. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. The company also offers oncology and specialty solutions.
Company Info
MCKESSON CORP
6555 State Highway 161
Irving TEXAS 75039 US
CEO: Brian S. Tyler
Employees: 43000
Phone: 19724464800
MCKESSON CORP / MCK FAQ
What does MCKESSON CORP do?
McKesson Corp. engages in providing healthcare services. The company is headquartered in Irving, Texas and currently employs 43,000 full-time employees. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. The company also offers oncology and specialty solutions.
What is the stock price of MCKESSON CORP today?
The current stock price of MCK is 836.43 USD. The price increased by 1.97% in the last trading session.
Does MCK stock pay dividends?
MCKESSON CORP (MCK) has a dividend yield of 0.4%. The yearly dividend amount is currently 2.71.
What is the ChartMill rating of MCKESSON CORP stock?
MCK has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
How is the valuation of MCKESSON CORP (MCK) based on its PE ratio?
The PE ratio for MCKESSON CORP (MCK) is 24.98. This is based on the reported non-GAAP earnings per share of 33.48 and the current share price of 836.43 USD.
How many employees does MCKESSON CORP have?
MCKESSON CORP (MCK) currently has 43000 employees.
What is the next earnings date for MCK stock?
MCKESSON CORP (MCK) will report earnings on 2025-11-05, after the market close.
MCK Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to MCK. When comparing the yearly performance of all stocks, MCK is one of the better performing stocks in the market, outperforming 86.79% of all stocks.
MCK Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to MCK. Both the profitability and the financial health of MCK get a neutral evaluation. Nothing too spectacular is happening here.
MCK Financial Highlights
Over the last trailing twelve months MCK reported a non-GAAP Earnings per Share(EPS) of 33.48. The EPS increased by 19.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.84% | ||
| ROA | 3.89% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MCK Forecast & Estimates
22 analysts have analysed MCK and the average price target is 854.2 USD. This implies a price increase of 2.12% is expected in the next year compared to the current price of 836.43.
For the next year, analysts expect an EPS growth of 16.97% and a revenue growth 12.75% for MCK